Stoke Therapeutics, Inc. — Director's Dealing 2021

Mar 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Stoke Therapeutics, Inc. (STOK)
CIK: 0001623526
Period of Report: 2021-03-02

Reporting Person: Ticho Barry (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-03-02	Employee Stock Option (Right to Buy)	$60.00	A	65600	Acquired	2031-03-01	Common Stock (65600)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	173631	Direct

Footnotes

F1: Includes 229 shares of Common Stock acquired under the issuer's employee stock purchase plan on December 31, 2020.

F2: The option vests as to 1/48th of the total shares on April 2, 2021 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.